ATN-224 is primarily utilized in the field of medical research, particularly in studies focusing on cancer treatment. It functions as a copper-zinc superoxide dismutase inhibitor, which plays a crucial role in modulating oxidative stress within cells. By inhibiting this enzyme, ATN-224 can potentially disrupt the redox balance in cancer cells, making them more susceptible to apoptosis or other forms of cell death. This mechanism is particularly explored in the context of prostate cancer, where it has shown promise in preclinical studies. Additionally, ATN-224 is being investigated for its potential to enhance the efficacy of other cancer therapies, such as chemotherapy and radiation, by sensitizing tumor cells to these treatments. Its application extends to understanding the role of oxidative stress in various other diseases, providing insights that could lead to the development of novel therapeutic strategies.